Maya-López Marisol, Colín-González Ana Laura, Aguilera Gabriela, de Lima María Eduarda, Colpo-Ceolin Ana, Rangel-López Edgar, Villeda-Hernández Juana, Rembao-Bojórquez Daniel, Túnez Isaac, Luna-López Armando, Lazzarini-Lechuga Roberto, González-Puertos Viridiana Yazmín, Posadas-Rodríguez Pedro, Silva-Palacios Alejandro, Königsberg Mina, Santamaría Abel
Laboratorio de Aminoácidos Excitadores, Instituto Nacional de Neurología y Neurocirugía, SSAMexico City 14269, Mexico; Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-IztapalapaMexico City 09310, Mexico.
Laboratorio de Aminoácidos Excitadores, Instituto Nacional de Neurología y Neurocirugía, SSA Mexico City 14269, Mexico.
Am J Transl Res. 2017 Feb 15;9(2):261-274. eCollection 2017.
The endocannabinoid system (ECS), and agonists acting on cannabinoid receptors (CBr), are known to regulate several physiological events in the brain, including modulatory actions on excitatory events probably through N-methyl-D-aspartate receptor (NMDAr) activity. Actually, CBr agonists can be neuroprotective. The synthetic CBr agonist WIN55,212-2 acts mainly on CB1 receptor. In turn, the mitochondrial toxin 3-nitropropionic acid (3-NP) produces striatal alterations in rats similar to those observed in the brain of Huntington's disease patients. Herein, the effects of WIN55,212-2 were tested on different endpoints of the 3-NP-induced toxicity in rat brain synaptosomes and striatal tissue. Motor activity was also evaluated. The 3-NP (1 mM)-induced mitochondrial dysfunction and lipid peroxidation was attenuated by WIN55,212-2 (1 µM) in synaptosomal fractions. The intrastriatal bilateral injection of 3-NP (500 nmol/µL) to rats increased lipid peroxidation and locomotor activity, augmented the rate of cell damage, and decreased the striatal density of neuronal cells. These alterations were accompanied by transcriptional changes in the NMDA (NR1 subunit) content. The administration of WIN55212-2 (1 mg/kg, i.p.) to rats for six consecutive days, before the 3-NP injection, exerted preventive effects on all alterations elicited by the toxin. The prevention of the 3-NP-induced NR1 transcriptional alterations by the CBr agonist together with the increase of CB1 content suggest an early reduction of the excitotoxic process via CBr activation. Our results demonstrate a protective role of WIN55,212-2 on the 3-NP-induced striatal neurotoxicity that could be partially related to the ECS stimulation and induction of NMDAr hypofunction, representing an effective therapeutic strategy at the experimental level for further studies.
内源性大麻素系统(ECS)以及作用于大麻素受体(CBr)的激动剂,已知可调节大脑中的多种生理事件,包括可能通过N-甲基-D-天冬氨酸受体(NMDAr)活性对兴奋性事件的调节作用。实际上,CBr激动剂具有神经保护作用。合成的CBr激动剂WIN55,212-2主要作用于CB1受体。反过来,线粒体毒素3-硝基丙酸(3-NP)在大鼠中产生的纹状体改变与亨廷顿病患者大脑中观察到的改变相似。在此,测试了WIN55,212-2对3-NP诱导的大鼠脑突触体和纹状体组织毒性的不同终点的影响。还评估了运动活性。在突触体组分中,WIN55,212-2(1μM)减轻了3-NP(1 mM)诱导的线粒体功能障碍和脂质过氧化。向大鼠脑内双侧注射3-NP(500 nmol/μL)会增加脂质过氧化和运动活性,提高细胞损伤率,并降低纹状体神经元细胞密度。这些改变伴随着NMDA(NR1亚基)含量的转录变化。在注射3-NP之前,连续六天给大鼠腹腔注射WIN55212-2(1 mg/kg),对毒素引起的所有改变均具有预防作用。CBr激动剂对3-NP诱导的NR1转录改变的预防作用以及CB1含量的增加表明,通过CBr激活可早期减轻兴奋性毒性过程。我们的结果证明了WIN55,212-2对3-NP诱导的纹状体神经毒性具有保护作用,这可能部分与ECS刺激和NMDAr功能减退的诱导有关,代表了实验水平上进一步研究的有效治疗策略。